• Most Popular
  • Most Shared

EU extends review of Teva bid for Barr Pharma

Tue Dec 2, 2008 5:27am EST

Stocks

   

BRUSSELS, Dec 2 (Reuters) - The European Commission on Tuesday extended its review of Israeli drugmaker Teva Pharmaceutical's (TEVA.O) bid to acquire U.S. biopharmaceutical and generic drugs marketer Barr Pharmaceuticals Inc BRL.N.

Stocks  |  Regulatory News  |  Mergers & Acquisitions  |  Global Markets

The deadline was moved to Dec. 22 from Dec. 8 in order to consider remedies to perceived competition concerns, the Commission said in a daily list of mergers under scrutiny.

Israel-based Teva, the world's largest generic drug company, in July said it would buy rival Barr for $7.46 billion to expand its leadership in the U.S. market and bolster its presence in Europe.

Both companies received requests for additional information regarding the planned merger from U.S. regulators in September.

(Reporting by Jan Strupczewski, editing by Dale Hudson)

Stocks
Regulatory News
Mergers & Acquisitions
Global Markets


More from Reuters

Photo

Investors seen jumping the gun on airport security

BANGALORE (Reuters) - Investors' optimism surrounding the shares of airport security systems makers could be premature as interest in the companies' products after the Christmas Day plane scare is not expected to translate into immediate orders.

» More Top News
Leaves gather in front of an empty and boarded-up house in Youngstown, Ohio November 21, 2009. REUTERS/Brian Snyder

Castles built on sand

Rust-belt American cities like Youngstown, Ohio were battered by the downturn. Now they're ready to move on, but it won’t be easy. The first in a three-part report.  Full Article 

Route to Recovery
REUTERS/James Saft
JAMES SAFT:

Welcome to the "Teenies"

Shrinking financial sector? Paltry investment returns? Welcome to the the next decade. Don't worry, there's some good news, too.  Commentary 

COMMENTARY